Plain-English translation of NCT04504747 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research study is trying to understand why some breast cancers stop responding to chemotherapy — a major problem that affects treatment outcomes. Researchers will collect blood samples and small pieces of tumor tissue from women receiving chemotherapy before surgery, then study these samples in the lab to discover which molecular changes predict whether a tumor will resist treatment.
Even though chemotherapy helps many women with aggressive breast cancer, about half of those with certain types don't achieve a complete response. Doctors don't yet have reliable ways to predict which patients will be resistant, so this study aims to find biological markers that could eventually help personalize treatment and improve survival.
You likely qualify if…
You likely don't qualify if…
You would have blood samples and small biopsies collected before you start chemotherapy and possibly at other time points during your treatment. These samples would be stored and studied by researchers looking for molecular patterns that predict treatment response. You'll continue receiving your standard chemotherapy and surgery as planned — this study adds only the sampling procedures to your regular care. The study involves 150 women total and follows standard ethical guidelines.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
France
Sponsor
Institut Paoli-Calmettes
Enrollment target
~150 participants
Started
November 2022
Primary completion
December 2027
Age range
18 Years and older
Sex
Female only
Last updated on clinicaltrials.gov in June 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
j PAKRADOUNI, PharmD,PhD
Institut Paoli-Calmettes
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.